RetinalGenix Technologies Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jerry Katzman
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 1450 North Mcdowell Boulevard Apollo Beach CA United States of America 94954
- IPO Date
- Feb 24, 2022
- CIK
- 0001836295
- Website
- retinalgenix.com
- Similar Companies
- Business
- RetinalGenix Technologies Inc. is an ophthalmic research and development entity dedicated to advancing solutions for the screening, monitoring, diagnosis, and treatment of various ocular and sight-threatening conditions. Its innovations include the High-Resolution Retinal Imaging System, designed for broad retinal screening without pupil dilation, and the RetinalCam, a patient-operated home monitoring and imaging system that provides real-time alerts to healthcare providers. The company is also developing a proprietary DNA/RNA/GPS™ Pharmaco-Genetic Mapping™ platform for comprehensive profiling of systemic and retinal disorders, alongside therapeutic drug candidates for conditions such as dry age-related macular degeneration and Alzheimer's syndrome dementia. Recent strategic alliances include a collaboration with Seer Bio to explore biomarkers through combined imaging and proteomic profiling, and a partnership with RGEN Clinical Genotyping Laboratory to integrate retinal imaging with DNA genotyping for enhanced early disease detection. Established in 2017, the company maintains its corporate headquarters in Petaluma, California. RetinalGenix Technologies Inc. operates as a subsidiary of Sanovas Ophthalmology, LLC.
RetinalGenix Reports on its Science and Mission in Light of New AI-Driven Retinal Mapping Study
RetinalGenix Technologies Agrees To Hire M. Cory Zwerling as CFO, Interim COO
RetinalGenix Technologies Contracts with Seer Bio to Explore Early Detection of Neurodegenerative, Systemic, and Retinal Diseases
RetinalGenix Technologies and RGEN Clinical Genotyping Laboratory Announce Strategic Collaboration to Advance Early Detection of Neurodegenerative, Systemic, and Retinal Diseases
RetinalGenix Technologies Advances Home and Remote Monitoring Patent Portfolio, Positioning for the Future of Ocular and Systemic Disease Care
RetinalGenix Technologies Contracts with LabCorp to Support DNA/GPS Platform for Advanced Genetic and Retinal Health Screening
RetinalGenix Technologies Welcomes Dr. Taimour Langaee as Advisor for DNA GPS Pharmacogenetics Initiatives
RetinalGenix Technologies, Inc. Announces Laboratory Lease Agreement with Life Science Incubator MBC BioLabs
RetinalGenix Technologies to Participate at the 37th Annual Roth Conference
RetinalGenix Technologies Breakthrough in Real-Time 24/7 Remote Ocular Monitoring
RetinalGeniX™ Technologies Inc. Granted a Patent for System And Method For Visualization Of Ocular Anatomy
RetinalGeniX™ Technologies Inc. Contracts With MEDsan, Inc. to Provide Diagnostic Testing Services for Its Institutional Review Board to Conduct a Study to Personalize Medical Evaluations for Patients Receiving Treatment for Wet Macular Degeneration
RetinalGeniX Technologies Inc. Appoints Anatoly Dritschilo, M.D. to the Company's Medical Advisory Board
RetinalGeniX Technologies Inc. Appoints Dessy Boneva, MD, FACS to the Board of Directors
RetinalGeniX Technologies Inc. Announces Hiring of Interim CFO
RetinalGeniX Technologies Inc. Appoints Stephen Tannenbaum to the Company's Business Advisory Board
RetinalGeniX™ Technologies Inc. Announces the Submission of Two Provisional Patent Applications For Investigational Therapeutic Drugs
RetinalGeniX Contracts With Avania CRO to Provide Guidance for Interactions With FDA on Development of Two Drug Therapies and the RetinalCam™ Image Visualization Device
RetinalGeniX IRB Approved to Conduct Study to Personalize Medical Evaluations for Patients Receiving Treatment for Wet Macular Degeneration
RetinalGeniX Technologies Inc. Focuses on Prevention of Blindness and Early Detection of Multiple Systemic Diseases